Bio Green Med Solution, Inc. SEC filings BGMSP

Bio Green Med Solution, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Mar 31, 2010. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (listing notice). The company's fiscal year ends on December 31.

Bio Green Med Solution, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Oct 8, 2026 —
425 Filing Jun 4, 2026 —
DEFR14A Filing May 1, 2026 —
425 Filing Sep 12, 2025 —
EFFECT Filing Sep 11, 2025 —
425 Filing Sep 5, 2025 —
425 Filing Aug 25, 2025 —
CORRESP Letter to the SEC Aug 22, 2025 —
425 Filing Aug 13, 2025 —
EFFECT Filing Aug 4, 2025 —
CORRESP Letter to the SEC Jul 31, 2025 —
UPLOAD Letter from the SEC Jul 31, 2025 —
CORRESP Letter to the SEC Jul 30, 2025 —
EFFECT Filing Jul 25, 2025 —
UPLOAD Letter from the SEC Jul 25, 2025 —
CORRESP Letter to the SEC Jul 24, 2025 —
CORRESP Letter to the SEC Jul 24, 2025 —
425 Filing Jul 16, 2025 —
UPLOAD Letter from the SEC Jul 7, 2025 —
425 Filing Jul 7, 2025 —
DRS Filing Jun 27, 2025 —
UPLOAD Letter from the SEC Jun 20, 2025 —
DRS Filing Jun 16, 2025 —
EFFECT Filing Apr 29, 2025 —
CORRESP Letter to the SEC Apr 28, 2025 —
UPLOAD Letter from the SEC Apr 14, 2025 —
DRS Filing Apr 10, 2025 —
NT 10-K Filing Mar 31, 2025 Dec 31, 2024
D Filing Mar 25, 2025 —
SC 14F1 Filing Mar 5, 2025 —
D Filing Feb 14, 2025 —
D Filing Feb 14, 2025 —
PRER14A Filing Jan 10, 2025 —
D Filing Nov 26, 2024 —
RW Filing Nov 7, 2024 —
D Filing May 17, 2024 —
EFFECT Filing May 13, 2024 —
CORRESP Letter to the SEC May 10, 2024 —
UPLOAD Letter from the SEC May 10, 2024 —
RW Filing Apr 29, 2024 —
EFFECT Filing Feb 13, 2024 —
CORRESP Letter to the SEC Feb 12, 2024 —
CORRESP Letter to the SEC Feb 7, 2024 —
UPLOAD Letter from the SEC Jan 26, 2024 —
NT 10-Q Filing Nov 15, 2023 Sep 30, 2023
EFFECT Filing Sep 13, 2023 —
CORRESP Letter to the SEC Sep 11, 2023 —
UPLOAD Letter from the SEC Sep 7, 2023 —
D Filing Jan 4, 2021 —
EFFECT Filing Apr 20, 2020 —
CORRESP Letter to the SEC Apr 16, 2020 —
UPLOAD Letter from the SEC Mar 16, 2020 —
EFFECT Filing Jun 21, 2019 —
CORRESP Letter to the SEC Jun 20, 2019 —
UPLOAD Letter from the SEC Jun 12, 2019 —
CT ORDER Filing Nov 19, 2018 —
EFFECT Filing Jul 18, 2017 —
CORRESP Letter to the SEC Jul 17, 2017 —
CORRESP Letter to the SEC Jul 17, 2017 —
CORRESP Letter to the SEC Jul 6, 2017 —
UPLOAD Letter from the SEC Jul 6, 2017 —
CORRESP Letter to the SEC Jun 30, 2017 —
UPLOAD Letter from the SEC Jun 9, 2017 —
EFFECT Filing Jun 8, 2016 —
CORRESP Letter to the SEC Jun 7, 2016 —
CORRESP Letter to the SEC Jun 3, 2016 —
UPLOAD Letter from the SEC May 9, 2016 —
EFFECT Filing Apr 29, 2013 —
EFFECT Filing Apr 29, 2013 —
EFFECT Filing Apr 29, 2013 —
EFFECT Filing Apr 29, 2013 —
EFFECT Filing Apr 29, 2013 —
EFFECT Filing Apr 22, 2013 —
CORRESP Letter to the SEC Apr 19, 2013 —
CORRESP Letter to the SEC Apr 18, 2013 —
UPLOAD Letter from the SEC Apr 17, 2013 —
EFFECT Filing Jan 16, 2013 —
CORRESP Letter to the SEC Jan 15, 2013 —
CT ORDER Filing Jan 11, 2013 —
UPLOAD Letter from the SEC Jan 3, 2013 —
D Filing May 1, 2012 —
EFFECT Filing Apr 26, 2012 —
EFFECT Filing Apr 26, 2012 —
EFFECT Filing Apr 26, 2012 —
EFFECT Filing Apr 26, 2012 —
CORRESP Letter to the SEC Apr 25, 2012 —
CORRESP Letter to the SEC Apr 25, 2012 —
CORRESP Letter to the SEC Apr 25, 2012 —
CORRESP Letter to the SEC Apr 25, 2012 —
UPLOAD Letter from the SEC Apr 25, 2012 —
CORRESP Letter to the SEC Apr 24, 2012 —
CORRESP Letter to the SEC Apr 24, 2012 —
CORRESP Letter to the SEC Apr 24, 2012 —
CORRESP Letter to the SEC Apr 24, 2012 —
CORRESP Letter to the SEC Apr 19, 2012 —
PRER14A Filing Apr 17, 2012 —
CORRESP Letter to the SEC Apr 17, 2012 —
UPLOAD Letter from the SEC Apr 13, 2012 —
UPLOAD Letter from the SEC Apr 11, 2012 —
UPLOAD Letter from the SEC Apr 11, 2012 —
UPLOAD Letter from the SEC Apr 11, 2012 —
UPLOAD Letter from the SEC Apr 11, 2012 —
CT ORDER Filing Sep 27, 2011 —
EFFECT Filing Jun 2, 2011 —
EFFECT Filing Jun 2, 2011 —
EFFECT Filing Jun 2, 2011 —
CORRESP Letter to the SEC May 31, 2011 —
CORRESP Letter to the SEC May 31, 2011 —
CORRESP Letter to the SEC May 31, 2011 —
CORRESP Letter to the SEC May 27, 2011 —
CORRESP Letter to the SEC May 27, 2011 —
CORRESP Letter to the SEC May 27, 2011 —
UPLOAD Letter from the SEC May 23, 2011 —
UPLOAD Letter from the SEC May 23, 2011 —
UPLOAD Letter from the SEC May 23, 2011 —
EFFECT Filing Apr 26, 2011 —
CORRESP Letter to the SEC Apr 22, 2011 —
CORRESP Letter to the SEC Apr 14, 2011 —
UPLOAD Letter from the SEC Apr 13, 2011 —
EFFECT Filing Dec 6, 2010 —
CORRESP Letter to the SEC Dec 1, 2010 —
CORRESP Letter to the SEC Nov 29, 2010 —
UPLOAD Letter from the SEC Nov 17, 2010 —
D Filing Oct 21, 2010 —
EFFECT Filing Jun 22, 2010 —
EFFECT Filing Jun 22, 2010 —
CORRESP Letter to the SEC Jun 18, 2010 —
CORRESP Letter to the SEC Jun 18, 2010 —
CORRESP Letter to the SEC Jun 18, 2010 —
CORRESP Letter to the SEC Jun 18, 2010 —
UPLOAD Letter from the SEC Jun 16, 2010 —
UPLOAD Letter from the SEC Jun 16, 2010 —
RW Filing Jun 11, 2010 —
CORRESP Letter to the SEC Jun 11, 2010 —
UPLOAD Letter from the SEC Jun 9, 2010 —
UPLOAD Letter from the SEC May 25, 2010 —
CORRESP Letter to the SEC May 19, 2010 —
NT 10-Q Notification of late filing May 18, 2010 Mar 31, 2010
UPLOAD Letter from the SEC May 14, 2010 —

Showing 139 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Wholesale-Durable Goods, NEC (SIC 5099)
Listed as
BGMS (Nasdaq), BGMSP (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Berkeley Heights, NJ
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1130166
Former names
Cyclacel Pharmaceuticals, Inc. (until Sep 12, 2025); XCYTE THERAPIES INC (until Mar 24, 2006)

Other Wholesale-Durable Goods, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.